Menopause and Perimenopause Remote Care

Menopause care has been one of the more underserved areas of medicine for decades, and the recent wave of menopause-focused telehealth services has filled a real gap. The flip side is a market in which "menopause clinic" can mean a thoughtful prescriber working through a careful workup, or a website that hands out a single prescription regardless of the patient. This page covers what good remote menopause care looks like.

The short version

Hormone therapy options include systemic estrogen, a progestogen if the uterus is intact, and vaginal estrogen for genitourinary symptoms.
Off-label testosterone for women is sometimes prescribed; evidence is more limited and largely focused on hypoactive sexual desire disorder in postmenopausal women.
The Menopause Society (formerly NAMS) publishes position statements that are the most cited reference in the field.
Baseline screening expectations include blood pressure measurement, age-appropriate mammography, and cervical cancer screening.
The Women's Health Initiative findings reshaped HRT prescribing in the 2000s; the field has since revisited the original interpretation, particularly for women starting therapy near the onset of menopause.
A good remote service personalizes the conversation; a poor one offers one regimen for everyone.

What menopause care should cover

Menopause is a clinical diagnosis based on symptoms and menstrual history, not primarily a lab result. For most women, the transition begins in their forties and progresses for years before the final menstrual period. Symptoms may include hot flashes and night sweats (vasomotor symptoms), sleep disturbance, mood changes, cognitive complaints, vaginal dryness and pain with intercourse, urinary symptoms, joint and muscle aches, and changes in skin and hair.

Treatment is individualized. The conversation should cover symptom severity, medical history (especially cardiovascular history, history of breast or endometrial cancer, history of blood clots, migraine with aura), screening status, and personal preferences. A reasonable initial evaluation is at least 30 minutes; many menopause-focused services schedule longer initial visits to do this work.

Hormone therapy basics

Systemic estrogen

Estradiol is the most commonly used systemic estrogen. It comes as a pill, patch, gel, spray, or vaginal ring (the latter at systemic doses). Transdermal forms (patch, gel, spray) bypass first-pass liver metabolism and may have different risk profiles than oral formulations, particularly for blood clots, although individual decisions are still based on the full clinical picture. Conjugated estrogens are also available.

Progestogens

For women with a uterus, a progestogen is added to systemic estrogen to protect the endometrium. Micronized progesterone is widely used; synthetic progestins are alternatives. The dose, timing, and form matter and should be addressed explicitly by the prescriber.

Vaginal estrogen

For genitourinary symptoms (dryness, pain, recurrent urinary tract infections related to menopause), low-dose vaginal estrogen — as a cream, ring, or tablet — is highly effective and has minimal systemic absorption. It is sometimes used in women who cannot use systemic estrogen.

Off-label testosterone

Testosterone in women is used off-label, primarily for hypoactive sexual desire disorder in postmenopausal women, and there is no FDA-approved testosterone product for women in the US. Evidence is more limited than for estrogen and progesterone, and dosing requires careful titration to avoid androgenic side effects. A prescriber should discuss this honestly rather than presenting it as routine.

Non-hormonal options

For vasomotor symptoms in women who cannot or prefer not to use hormones, non-hormonal options include certain SSRIs and SNRIs, gabapentin, clonidine, and a newer class of neurokinin-3 receptor antagonists. Each has its own profile. A service that does not mention non-hormonal options when relevant is incomplete.

The Women's Health Initiative and what changed

The Women's Health Initiative was a large randomized trial that, in the early 2000s, was interpreted as showing increased risks of breast cancer, cardiovascular events, and stroke in women on combination HRT. The result was a sharp drop in HRT prescribing and a generation of women going through menopause without it.

Subsequent re-analyses and additional studies have led to a more nuanced view. For symptomatic women starting therapy near the onset of menopause and within roughly ten years of the final menstrual period, the risk-benefit calculus is more favorable than the original WHI headlines suggested. The Menopause Society and other professional bodies generally support the use of hormone therapy for symptomatic women without contraindications, with individualized risk discussion. None of this means HRT is risk-free; it means the discussion has nuance and a prescriber should be having it.

Required screening and labs

Menopause care does not happen in isolation. Reasonable expectations for a remote menopause practice:

Up-to-date blood pressure measurement; home BP if relevant. See measuring your own vitals at home.
Age-appropriate mammography (typically annual or biennial in the relevant age range — the specific guideline varies by professional body and personal risk).
Up-to-date cervical cancer screening per current US Preventive Services Task Force guidance.
Lipid panel and other cardiovascular risk assessment as indicated.
Thyroid function if symptoms suggest possible thyroid contribution.
Discussion of bone health and bone density screening per guidelines.

A menopause service that prescribes HRT without ever asking about mammography, blood pressure, or cardiovascular history is not doing the work. Some services accept records from your primary care to document this; some require labs to be done locally before prescribing.

Compounded vs. FDA-approved

"Bioidentical" is a marketing term, not a regulatory one. FDA-approved hormone therapies include products that are bioidentical (estradiol, micronized progesterone) — they are bioidentical and FDA-approved. Custom-compounded hormone preparations are different: they are made by compounding pharmacies for individual patients, are not FDA-approved, and have not undergone the same testing for purity, potency, and labeling consistency. The Menopause Society and the FDA have both raised concerns about routine use of compounded hormones when an FDA-approved option is available. There are legitimate uses for compounded hormones (allergy to a component of an FDA-approved product, specific dose unavailable commercially), but a service that defaults to compounded products for everyone is a flag.

What a good remote menopause service does

Spends time on a real history, not a quick form.
Asks about cardiovascular, breast, and endometrial history; blood clot history; migraine with aura.
Confirms or coordinates age-appropriate screening.
Explains options — including non-hormonal — and the rationale for the recommended one.
Discusses risk transparently rather than dismissing concerns.
Adjusts treatment based on response, not on a fixed protocol.
Will see patients again if symptoms persist or change.
Coordinates with primary care.

What to ask a menopause-focused service

Are you a menopause-trained clinician? Are you a Menopause Society Certified Practitioner (MSCP)?
What screening do you confirm before prescribing? Do you require my records?
What are the risk discussions you have around breast cancer, cardiovascular disease, and clotting?
Do you prescribe FDA-approved products, compounded products, or both?
Will you communicate with my primary care?
What happens if symptoms do not improve or side effects develop?
What does ongoing care look like — visit cadence, lab schedule, refill process?

Insurance, cost, and continuity

Menopause-focused services sometimes operate as cash-pay practices outside insurance. Costs include initial evaluation, ongoing visits, medications (which may or may not be covered by insurance even if the visit is not), and any compounded prescriptions (which are often not covered). For longevity of care, continuity with a single clinician matters; switching menopause prescribers every few months produces fragmented care. See choosing remote specialty care and insurance and telehealth.

Red flags

Diagnosis from a brief questionnaire with no clinician interaction.
One-size-fits-all prescription regardless of history.
No screening or screening history requested.
Heavy push toward compounded products without clinical reason.
Vague claims about "bioidentical" without distinguishing FDA-approved from compounded.
No clear policy for managing side effects or non-response.
Refusal to communicate with primary care.

For broader patterns, see red flags in any remote care service.

When this is not enough

For new abnormal uterine bleeding, severe pelvic pain, breast lumps, or any symptom suggesting an underlying cancer, in-person evaluation with imaging and possible biopsy is essential. For complex medical histories — recent breast cancer, recent venous thromboembolism, complex cardiovascular disease — care is best handled with the involvement of the original specialists. See when telehealth is not enough.

Menopause and perimenopause remote care